Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Fluorescent nanodiamonds combine the advantages of semiconductor quantum dots (small size, high photostability, bright multicolor fluorescence) with biocompatibility, non-toxicity, and rich surface chemistry, which means that they have the potential to revolutionize Vivo imaging applications.
The intracellular KOR signaling axis involves continued Gi/o coupling on late endosomal membranes, sustained suppression of adenylyl cyclase and cAMP production, and prolonged recruitment of ERK pathway components through Gβγ-dependent mechanisms, thereby establishing a biochemical niche for chronic dynorphin signaling distinct from acute plasma membrane responses. This signaling permits differential integration of intracellular second messenger systems and transcriptional responses compared to plasma membrane-restricted coupling.
An opioidergic agent (or drug) is a chemical which directly or indirectly modulate the function of opioid receptors. Opioidergics comprise opioids, as well as allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.
Chemical information, Clinical information and Biochemical information. The chemical data includes >40,000 metabolite structures with detailed descriptions, extensive chemical classifications, synthesis information and observed/calculated chemical properties. It also contains nearly 10,000 experimentally measured NMR, GC-MS and LC/MS spectra from more than 1,100 different metabolites. The clinical information includes data on >10,000 metabolite-biofluid concentrations, metabolite concentration information on more than 600 different human diseases and pathway data for more than 200 different inborn errors of metabolism. The biochemical information includes nearly 6,000 protein (and DNA) sequences and more than 5,000 biochemical reactions that are linked to these metabolite entries. The HMDB supports a wide variety of online queries including text searches, chemical structure searches, sequence similarity searches and spectral similarity searches. This makes it particularly useful for metabolomic researchers who are attempting to identify or understand metabolites in clinical metabolomic studies. The first version of the HMDB was released in Jan. 1 2007 and was compiled by scientists at the University of Alberta and the University of Calgary. At that time, they reported data on 2,500 metabolites, 1,200 drugs and 3,500 food components. Since then these scientists have greatly expanded the collection. The version 3.5 of the HMDB contains >16,000 endogenous metabolites, >1,500 drugs and >22,000 food constituents or food metabolites.
War of the Spanish Succession (1701–1714), concluded by the Peace of Utrecht and redrawing dynastic and colonial boundaries. War of the Austrian Succession (1740–1748), contesting Habsburg succession and reshaping Central Europe. Seven Years' War (1756–1763), the first truly global conflict, spanning Europe, North America (known in the US as the French and Indian War), India and the Caribbean. Onset of the Industrial Revolution (c. 1760), beginning in Britain with mechanization of textile production and development of the steam engine. American Revolution (1775–1783), resulting in the independence of the United States of America. French Revolution (1789–1799), which overthrew the Bourbon monarchy and established the First French Republic. Ottoman Old Regime (1703–1789) followed by the decline and modernization of the Ottoman Empire.
Sources: en.wikipedia.org
Clonidine, sold under the brand names Catapres and Kapvay, among others, is an α2-adrenergic receptor agonist, hypotensive, sedative and anxiolytic drug used to treat high blood pressure, attention deficit hyperactivity disorder, perioperative pain, drug withdrawal (e.g., alcohol, opioids, or nicotine), and menopausal flushing. Clonidine is sometimes prescribed off-label for tics. It is used orally (by mouth), by injection, or as a transdermal skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours. Xylazine is a structural analog of clonidine. Common side effects include dry mouth, dizziness, headaches, hypotension, and sleepiness. Severe side effects may include hallucinations, heart arrhythmias, and confusion. If rapidly stopped, withdrawal effects may occur, such as a dangerous rise in blood pressure. Use during pregnancy or breastfeeding is not recommended. Clonidine lowers blood pressure by stimulating α2-adrenergic receptors and imidazoline receptors in the brain, which results in relaxation of many arteries. Clonidine was patented in 1961 and came into medical use in 1966. It is available as a generic medication. In 2023, it was the 82nd most commonly prescribed medication in the United States, with more than 8 million prescriptions.
There is usually an indication for a specific identification of an infectious agent only when such identification can aid in the treatment or prevention of the disease, or to advance knowledge of the course of an illness prior to the development of effective therapeutic or preventative measures. For example, in the early 1980s, prior to the appearance of AZT for the treatment of AIDS, the course of the disease was closely followed by monitoring the composition of patient blood samples, even though the outcome would not offer the patient any further treatment options. In part, these studies on the appearance of HIV in specific communities permitted the advancement of hypotheses as to the route of transmission of the virus. By understanding how the disease was transmitted, resources could be targeted to the communities at greatest risk in campaigns aimed at reducing the number of new infections. The specific serological diagnostic identification, and later genotypic or molecular identification, of HIV also enabled the development of hypotheses as to the temporal and geographical origins of the virus, as well as a myriad of other hypothesis. The development of molecular diagnostic tools have enabled physicians and researchers to monitor the efficacy of treatment with anti-retroviral drugs. Molecular diagnostics are now commonly used to identify HIV in healthy people long before the onset of illness and have been used to demonstrate the existence of people who are genetically resistant to HIV infection.
=== Libertarianism and capitalism === In a 2001 interview with Reason, Hitchens said he had been interested in libertarian ideas when he was younger, but set aside those interests in the 1960s. He stated that capitalism had become the more revolutionary economic system, and he welcomed globalisation as "innovative and internationalist", but added, "I don't think that the contradictions, as we used to say, of the system, are by any means all resolved." He also stated that he had a renewed interest in the freedom of the individual from the state, but that he still considered libertarianism "ahistorical" both on the world stage and in the work of creating a stable and functional society, adding that libertarians are "more worried about the over-mighty state than the unaccountable corporation" whereas "the present state of affairs ... combines the worst of bureaucracy with the worst of the insurance companies." He also said that libertarians did not have a clear foreign policy stance. In a 2001 C-SPAN appearance, he told a caller:
=== Computing === Network processing unit, hardware for networking Neural processing unit, hardware for artificial intelligence Numeric processing unit, or floating-point unit, hardware for floating-point numbers
Sources: en.wikipedia.org
=== Cartilage implants === In July 2016, the U.S. approved the use of a synthetic cartilage implant to treat arthritis in the joint of the big toe. The implant is made of saline and a bio-compatible polymer, and is inserted through an incision between the metatarsophalangeal (MTP) joint where natural cartilage has worn away. It is being researched for use in other joints. A separate orthopedic implant consisting of a hydrated, interpenetrating dual polymer network based on polyether urethane (PEU) was given breakthrough device designation from the U.S. Food and Drug Administration in July 2021. In September 2021, researchers used nasal chondrocyte-based engineered cartilage to treat osteoarthritic joints in two patients.
== History of the taxonomy == Prior to 1993, the family Conidae contained only Conus species. In 1993 significant taxonomic changes were proposed by Taylor, et al.,: the family Conidae was redefined as several subfamilies. The subfamilies included many subfamilies that had previously been classified in the family Turridae, and the Conus species were moved to the subfamily Coninae. In further taxonomic changes that took place in 2009 and 2011, based upon molecular phylogeny (see below), the subfamilies that were previously in the family Turridae were elevated to the status of families in their own right. This left the family Conidae once again containing only those species that were traditionally placed in that family: the cone snail species.
==== Tax deduction for qualified tip income ==== The law creates new tax deductions for tips of up to $25,000 per year received by workers earning less than $150,000, with the tax deduction set to expire in 2028. In order to be eligible, a tip must be paid voluntarily by the payor, and the payor must determine the amount of the tip. The payor must not be subject to a penalty if they do not pay a tip, and the tips must not be subject to any negotiation. The tip must be given to workers working one of 68 different job types. Tips received while performing a service that is a felony or misdemeanor are not eligible. Tips received for prostitution or pornography are not eligible. Tips received as part of a tip pool are generally eligible. Tips received directly by a supervisor or manager are eligible only if they are for services they provided in a qualified occupation and not as part of a tip pool. If the customer is charged a service charge or an automatic tip amount that is not voluntary on the part of the customer, then the service charge or tip is not eligible. This includes if the company requires a customer to pay a service charge or a particular tip amount on parties greater than a certain size. Voluntary tips above such a minimum or mandatory charge are eligible. Recommended tips are eligible if they are optional on the part of the payer. If the customer is required to select a tip amount but does not have the option to choose to not tip at all, the minimum possible tip amount is not eligible but any tips exceeding that minimum are eligible.
In June 2022, FCC Commissioner Brendan Carr called for Google and Apple to remove TikTok from their app stores, saying sensitive data were being accessed from Beijing and ByteDance would be "required by law to comply with [Chinese government] surveillance demands." In November 2022, Christopher A. Wray, director of the Federal Bureau of Investigation (FBI), said the Chinese government could use TikTok for influence operations on its users. In May 2023, a former ByteDance employee filed a wrongful termination lawsuit alleging that Hong Kong users' device information and communications, particularly those of demonstrators in the 2019–2020 Hong Kong protests, were accessed by Chinese Communist Party members in 2018. ByteDance denied the claims, saying the employee worked on a defunct project and that TikTok was pulled out of Hong Kong in 2020. The whistleblower claimed in a sworn court statement that his father in mainland China had been detained by the authorities in retaliation for his speaking to the media about alleged censorship by TikTok. In June 2023, TikTok confirmed that some financial information, such as tax forms and Social Security numbers, of American content creators are stored in China. This applies to those signing contracts with and receiving payment transactions from ByteDance. Whether similar information will remain exempt from being treated as "protected user data" is being negotiated with Committee on Foreign Investment in the United States (CFIUS).
==== Cytokines ==== Illness can cause inflammation, which often involves an increase in cytokines such as TNFa, IL-1, and IL-6. Cytokines are implicated in NTIS. IL-1β has been shown to decrease liver D1, as well as thyroid hormone receptor (THR) levels. IL-6 and TNFa downregulate D1 and suppress TSH, are negatively correlated with fT3, and are positively correlated with rT3. NF-κB also inhibits D1, and decreases the expression of Thyroid receptors α and β. IFNy inhibits thyroid and Tg release, and also inhibits the upregulation of TSH receptors.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.